Conversion to brivaracetam monotherapy in clinical practice was associated with high 6- and 12-month retention.

The rates of seizure freedom were 72.7% and 58.1% at 6- and 12-month follow-up.

Treatment retention and seizure freedom rates were higher among people who switched from levetiracetam.

Brivaracetam monotherapy was generally well tolerated, and somnolence, fatigue, and irritability were the most common adverse events.